GAMMA Investing’s Corvus Pharmaceuticals CRVS Stock Holding History

GAMMA Investing’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$13.2K	Buy	1,149 +470	+69%	+$6.55K	﹤0.01%	3185
2026 Q2	$10.1K	Buy	679 +79	+13%	+$1.1K	﹤0.01%	3197
2026 Q1	$8.78K	Buy	600 +457	+320%	+$7.29K	﹤0.01%	3135
2025 Q4	$1.1K	Buy	143 +49	+52%	+$386	﹤0.01%	3763
2025 Q3	$693	Buy	+94	New	+$481	﹤0.01%	3671

Other funds holding CRVS

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

AIM

Avity Investment Management Greenwich, Connecticut $1.6B AUM 32.15% 1-Year Est. Return

Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

GAMMA Investing's CRVS Position: Q3 2026 in Review

GAMMA Investing increased its Corvus Pharmaceuticals (CRVS) stake by 69% in Q3 2026, buying an estimated $6.55K and bringing the position to 1,149 shares worth $13.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3185.

GAMMA Investing first reported a position in CRVS in Q3 2025 and has held it in 5 quarters since. 6 funds tracked by Wall St. Rank hold CRVS as of Q3 2026.

GAMMA Investing held 1,149 shares of Corvus Pharmaceuticals worth $13.2K as of Q3 2026.
GAMMA Investing bought 470 Corvus Pharmaceuticals shares in Q3 2026, an estimated $6.55K.
Corvus Pharmaceuticals made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #3185 holding.
GAMMA Investing first reported a position in Corvus Pharmaceuticals in Q3 2025 and has held it in 5 quarters since.
6 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.